Immunohisotchemical
Mapping of Hypoxia in
Ischemic Mouse Hindlimb
Skeletal Muscle
Microciruculation and Tissue Repair Lab
Dr. Trevor Cardinal, Advisor
Senior Project
August 2010
Emily Deckert

1

Table of Contents
ABSTRACT ................................................................................................................................... 1
INTRODUCTION ......................................................................................................................... 3
METHODS .................................................................................................................................... 5
Table 1. Injection Factors............................................................................................................................9
Table 2. Experimental Setup................................................................................................................... 13

RESULTS .................................................................................................................................... 13
Table 3. Staining Results .......................................................................................................................... 17
Successful Stains .............................................................................................................................. 18
Unsuccessful Stains ......................................................................................................................... 23

DİSCUSSİON .............................................................................................................................. 30
Table 4. Future Suggestions................................................................................................................... 32

REFERENCES ............................................................................................................................ 33
APPENDİX ................................................................................................................................. 34
Appendix A:
Appendix B:
Appendix C:
Appendix D:
Appendix E:

2

Injection Protocol .................................................................................................. 34
Staining Protocol ................................................................................................... 35
Alternate Staining Protocol................................................................................ 37
Staining Log ............................................................................................................. 39
Hypoxyprobe TM -1 Kit Information ................................................................. 40

ABSTRACT
The study of blood vessel growth and remodeling is a complex endeavor.
Hypoxia, the lack of oxygen in a tissue, is known to stimulate angiogenesis (the
growth of new blood vessels), and have little effect on arteriogenesis (the
enlargement of existing blood vessels). However, the role of hypoxia in vessel
function is unknown, but may be determined using the results and methods
developed in this experiment.
Supplied by the bloodstream, oxygen is required by all cells and tissues to
remain healthy. If the bloodstream supplying a certain tissue with blood is
disrupted, the tissue becomes ischemic, often leading to hypoxia. Hypoxia is the lack
of oxygen in living tissue; specifically tissue oxygen levels less than 10 mmHg
(hypoxyprobe.com).
When a tissue is ischemic, and therefore hypoxic, angiogenesis is known to
occur, which expands the nutrient and waste exchange capacity of the
microcirculation. Hypoxia-inducible factor (HIF) is a transcriptional regulator of
angiogenic molecular pathways and is regulated according to the oxygen availability
in a given tissue (Pugh, Ratcliffe).
By studying the locality of hypoxia within a given tissue, it is possible to
predict the behavior of the growing blood vessel. Additionally, changes in vessel
function may be understood by comparing the location of hypoxia with the location
of the altered function. Cal Poly’s microcirculation laboratory is interested in
investigating the effects of hypoxia, either prior or sustained, on vascular reactivity.
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In order to carry out this investigation, a method for assessing the level of hypoxia
throughout the tissue is needed.
In this study, immunohistochmeical staining techniques were used to visually
map hypoxia in ischemic mouse hindlimb skeletal muscle. The technique, which
was developed into a repeatable protocol, may be useful in further investigating
hypoxia induced vascular growth and changes in function.
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INTRODUCTION
Many physiological processes involve the control of tissue blood flow. Blood
flow control mechanisms act to maintain the functionality of blood, including
transportation of nutrients, regulation of pH levels, and defense against pathogens
(Marieb). Because of the wide oxygen demand (due to the wide metabolic range) of
skeletal muscle, the health of the tissue is critically dependent on acute blood flow
control. (Jain).
In cases of pathology, blood vessels can become occluded, affecting vascular
reactivity and blood flow control. Many things can occlude vessels, disrupting
normal blood flow. Atherosclerosis is a condition where the diameter of a blood
vessel is dramatically lessened due to a build up of fatty substances in the vessel
lumen (Maton). Ligation of the vessel prevents blood flow through the pathway to
some degree. Occlusion, due to atherosclerosis, ligation, or other causes, lessens or
eliminates blood flow through a vessel, causing the tissues normally supplied with
blood from those vessels to be ischemic. The ligation treatment experimentally
models ischemic conditions that would be found in response to pathologic arterial
occlusion, such as atherosclerosis.
Tissues respond complexly to arterial occlusion. If the occlusion causes
injury, inflammation can occur. Inflammation and hypoxia together may cause
myofiber death and regeneration, in which muscle fibers re-grow to repair the
damage that caused inflammation in the first place (Marieb). In addition to these
possibilities, injury or any other disruption to the flowing capacity of blood vessels
has two main results. First, arterial occlusion increases angiogenesis, the growth of
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new vessels from existing vessels, and may increase arteriogenesis, and the outward
remodeling of existing collateral vessels. These changes in microvascular
architecture help maintain sufficient oxygen delivery. Secondly, occlusion decreases
vessel wall function, in terms of the ability of the vessel to constrict or dilate
(Marieb). When vessel wall function is impaired, specifically by injury, the vessel
has less control over blood flow, thereby decreasing the microvascular function of
the vessel, and the health of the affected tissue.
Because vessel injury usually leads to ischemia, which tends to cause
hypoxia, hypoxia can be viewed as the catalyst for increased angiogenesis, and
decreased vessel wall function. The goal of Cal Poly’s Microcirculation and Tissue
Repair lab is to investigate how changes in vessel architecture, in terms of
angiogenesis, usually catalyzed by injury, affect blood flow, and why vessel injury
affects vessel wall function.
A common consequence of ischemia is hypoxia, where a tissue is deprived of
a certain level of oxygen (Marieb). Hypoxia, as a consistent consequence to blood
vessel injury, affects angiogenesis and perhaps vessel wall function. However, the
exact impact of hypoxia on vessel wall function is unknown. In order to understand
how hypoxia affects vessel wall function, the physical location of hypoxia needs to
be correlated to the physical locations of dysfunctional resistance vessels. This
correlation may reveal more specifically how hypoxia impacts vascular reactivity.
The focus of this study is to determine the geographical behavior of hypoxia in
ischemic tissues of the mouse hindlimb, which can further be used to understand
how hypoxia impacts vascular reactivity.
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METHODS
Overview
The purpose of this study was to develop a protocol for hypoxia mapping in
ischemic mouse hindlimb skeletal muscle that the microcirculation lab could use in
the future to examine the correlation between hypoxia and vascular function.
In this study, mice were used to map hypoxia in the calf muscle under
ischemic conditions. Pimonidazole was injected into the anesthetized mouse. Next,
the femoral and saphenous artery-vein pair were resected, such that the hindlimb
skeletal muscle became ischemic. The tissues were dissected, fixed in Histochoice,
processed, and embedded for histological use. Immunohistochemistry was then
used to stain cross sections of the ischemic hindlimb tissue for areas of hypoxia.
Three surgeries were completed, each of which differed slightly from the
others, in the attempt to achieve successful hypoxia maps. As was the staining
protocol, the injection and surgical protocols were developed during execution.
Process parameters were modified in the attempt to optimize the protocols.

Injection
Pimonidazole hydrochloride (Hypoxyprobe) was used as a hypoxia marker.
Once an intraperitoneal injection into the mouse was made, Hypoxyprobe bound to
hypoxic cells, or those cells with the partial pressure of oxygen less than 10 mmHg
at 37 deg C. However, the pimonidazole required time to diffuse into the
bloodstream and circulate throughout the body before it was able to even reach all
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hypoxic cells. In this sense, the injection timing was critical. In surgery 1, 25
minutes were allowed between injection and the first ligation of the resection
surgery. For surgery 2, 55 minutes were allowed between injection and initial
ligation. For surgery 3, 20 minutes were allowed for uptake and circulation of
pimonidazole by the blood after injection and before ligation.

Resection
In the next step of the surgery, the femoral artery-vein pair and saphenous
artery-vein pair were resected from the left hindlimb, according to the established
protocol developed by the microcirculation and tissue repair lab. To do this, the fur,
skin, connective tissue, and fat pad were removed so that the vasculature was
exposed on the medial aspect of the hindlimb. Two ligations were made, one
between the knee and ankle, and the other just upstream of the muscular branch.
Once ligated, the vessels between each suture were removed. This step, from the
first ligation to the second, took different amounts of time. For surgery 1, it took 4
minutes, for surgery 2, it took 25 minutes, and for surgery 3, it took 20 minutes. The
right hindlimb in all three surgeries was left untouched, so that ischemic conditions
were only induced in the left hindlimb skeletal muscle.

Perfusion Fixation
Perfusion fixation is a step, paired with a vasodilator cocktail, intended to
dilate, remove the blood from, and fix tissues throughout the entire body. The
purpose of fixation is to disable damaging biomolecules, protect the sample from
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foreign microorganisms, and increase the mechanical strength of the samples to
maintain the morphology of the tissue. The benefit of fixation is that it preserves the
vessels in a natural state, and allows them to be easily analyzed during histology.
Perfusion fixation is a method of fixation where the fixative is administered
through the blood stream. Enough fixative to enter every vessel was administered
into the heart and allowed to spread through the body. The tissues remained alive
until the moment the fixative reached them. In this way, tissue integrity was
maintained more than it would be with immersion fixation (where dissected tissues
are placed in a fixative). With immersion fixation, no administration of fixative
occurred through the bloodstream, and the fixative diffused throughout the organ.

Stimulation
Tungsten microelectrodes were used to stimulate muscle contraction.
Electrodes were impaled into to the calf muscle and used to deliver current for 90
seconds at 8 Hz, 0.5 ms, 2 mA. The resulting muscle contraction required ATP to
support actin-myosin cross bridge cycling. Oxygen in the calf skeletal muscle, which
was used in the production of ATP, was depleted by the induced muscular
contraction, and could not be restored by the bloodstream because of the resection.
Therefore, stimulation of skeletal hindlimb muscle after resection of the femoral and
saphenous artery-vein pair should have quickly depleted the tissue of oxygen,
leaving it highly hypoxic.
Following the resection step, the procedure varied greatly between surgeries.
For surgery 1, another period of waiting was implemented, this time 40 minutes, in
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order to allow the circulating Hypoxyprobe to bind to newly hypoxic cells. After this
period of waiting, a perfusion fixation was implemented, directly followed by tissue
harvest. In surgery 2, 35 minutes if wait-time was allowed after resection and
before tissue dissection, with no perfusion fixation step. Instead, tissues were fixed
by immersion directly following dissection. In surgery 3, stimulation was used in
the left calf only in an attempt to increase the level of hypoxia in the tissue. After
this, 20 minutes of rest were used to allow the Hypoxyprobe to bind to newly
hypoxic cells before dissection and immersion fixation.

Dissection
After either a period of waiting, or in the case of surgery 1, perfusion fixation,
tissues were dissected from the euthanized animal. The main tissues of interest for
the dissection were the calf and the gracilis muscle. These tissues were dissected
from the ischemic left, and non-ischemic right hindlimb, and immersed directly into
fixative. In surgery 1 and 2, Histochoice was used as a fixative. In surgery 3, the
tissue was fixed with formalin. All three sets of tissues were left immersed in
fixative for 24 hours before processing. The general injection protocol, subject to
the mentioned alterations, is attached in Appendix A. Below is a summary of the
differences between surgeries.
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Table 1. İnjection Factors
Surgery 1
Time from injection to resection start
26 min.
Time in resection
4 min.
Time from resection end to dissection
40 min.
start
Total time
70 min.
Stimulation?
No
Perfusion/fixation?
Yes
Fixative
Histochoice
Fixative temperature
Room
temperature

Surgery 2
57 min.
26 min.
35 min.

Surgery 3
21 min.
19 min.
34 min.

118 min.
No
No
Histochoice
4 deg C

74 min.
Yes
Yes
Formalin
4 deg C

Processing
Sample processing was required before the tissues could be embedded for
histological purposes. Processing involved two main steps: dehydration and
clearing. Tissues were placed in labeled cassettes and in an automatic processor.
The processing was done automatically over night. Dehydration involved removing
water from the samples, and consisted of a series of steps where the samples were
rinsed with increasing concentrations of alcohol. After dehydration, the tissue
underwent clearing. The purpose of clearing is to remove the dehydrating reagents
from the previous step, usually with xylene. Additionally, the processor infiltrated
the tissue with paraffin wax.

Embedding
Once the samples were dehydrated and cleared in the automatic processor,
they were embedded in paraffin wax. The tissues were cut in half along their crosssection, placed in hot wax and aligned in a plastic cassette. The wax was allowed to
cool and harden into a block ready for sectioning. To map hypoxia in the dissected,
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ischemic tissues, histological analysis was used. Eight μm sections of tissue were
taken with a microtome and placed on microscope slides.

Staining
In this study, immunohistochemistry (IHC) was used to stain for hypoxia.
Pimonidazole, which was injected into the animal before dissection, formed adducts
when bound to proteins in hypoxic cells, whıch were the antigen source for the IHC
stain. Therefore, a series of antibodies specific to pimonidazole-protein adducts
produced a visual representation of the hypoxic gradient when added to the
sectioned hypoxic tissues that were injected with pimonidazole.
The primary reagents in the immunohistochemical stain were the blocking
serum, primary antibody, secondary antibody, avaidin-biotin enzyme, and
peroxidase substrate. All of these reagents had crucial roles that contributed to the
resulting stain of hypoxic regions.
In this study, pimonidazole that was bound to protein in hypoxic
environments acted as the antigen. The level of pimonidazole binding was expected
to increase as the level of hypoxia increased. Pimonidazole labeled all hypoxic
tissue by binding proportionately to each one, resulting in darker staining where
more hypoxia existed. Non-specific binding of antibodies or enzymes to cells
without pimonidazole adducts was prevented by the blocking solution.
The next key factor in the general IHC staining process was the primary
antibody. The Hypoxyprobe kit included a mouse immunoglobulin monoclonal
antibody (MAb IgG1), which detected and binds only to pimonidazole antigens in the
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tissue. Next, a biotinylated secondary antibody was introduced to the tissue, which
bound with the primary antibody. Biotin, a B-complex vitamin, which was
conjugated to the secondary antibody, facilitated signal amplification in later steps.
After the biotinylated secondary antibody had bound to the primary antibody
(which was bound to the antigen), avidin was added. Avidin and biotin form strong
covalent bonds. In this case, avidin bound to the biotin molecule that was
conjugated to the secondary antibody, at the hypoxic site. Finally, biotinylated
peroxidase was added to the tissue. Each avidin molecule bound four biotin
molecules, so for each avidin bound to each biotinylated secondary antibody, there
were three biotinylated peroxidase molecules that attached to the complex. This
mechanism lead to sıgnal amplification, because more peroxidase molecules were
present than were pimonidazole adducts. The peroxidase developed an added
reagent, diaminobenzidne (DAB), into a brownish precipitate. When DAB was
added, it should only turn brown in the presence of peroxidase. In this way, the
more hypoxic the cell was, the darker brown it appeared. The results of the process
were stained tissues on microscope slides, appearing in shades of brown. If
successful, the degree of shading throughout each tissue cross-section correlated to
the amount of hypoxia present there at the time of harvest.
In this study, an ABC kit from Santa Cruz Biotechnology was used (ABC2017). The kit provided most of the undiluted reagents, such as blocking serum
stock, secondary antibody stock, avadin, biotinylated horse radish peroxidase,
substrate buffer, DAB chromagen, and peroxidase substrate. These reagents were
combined into steps and diluted in PBS or deionized water. For example, blocking
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serum stock and secondary antibody stock were provided components but were
separately diluted in PBS. The following are the consolidated IHC steps provided by
the ABC kit: blocking solution, secondary antibody, avidin-biotin enzyme, and
peroxidase substrate. Hypoxyprobe provided the primary antibody.
Just as the vague injection protocol provided by the Hypoxyprobe
manufacturer was interpreted several times to fit the needs of this study, so was the
existing IHC protocol. Originally, the Immunohistochemistry protocol was used for
staining alpha smooth muscle actin, with the ABC kit. The steps were altered before
and during trials to mold the protocol into one that produced successful hypoxia
maps. Several of the main alterations are as follows: lessening time in dehydration
steps, and changing the primary antibody (depending on the antigen stained for).
The most updated version of the staining protocol can be viewed in Appendix B.
Another IHC staining protocol, provided by Hypoxyprobe, was interpreted and used
for one run in this study (Appendix C). However, the modified alpha smooth muscle
actin protocol (Appendix B) was used for most runs, because the technique was
more straight forward, and the protocol had already produced successful results
with the smooth muscle actin antibody.
In this study, two different experimental conditions were implemented, so
that four different groups existed for each trial. The only group that should have
had positive staining was the ischemic primary group. This is because pimonidazole
IHC peroxidase staining only stains for hypoxia, which should only be present in
significant quantities in the ischemic tissue. Moreover, the success of the whole IHC
process depended on the presence of the primary antibody. Without the primary
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antibody, the rest of the reagents (secondary antibody, avidin, biotin, peroxidase,
and DAB) would not bind to or be developed near hypoxic cells, thereby failing to
create a dark shade and more importantly, a hypoxia map. Therefore, hypoxic
staining was only expected in ischemic tissues treated with primary antibody. The
conditions and groups used in this study are summarized below:

Primary Antibody

Table 2. Experimental Setup
Ischemic Tissue
Non-ischemic Tissue
Ischemic, Primary Group
Non-ischemic, Primary Group
(expected positive
results)

No Primary Antibody

Ischemic, Control Group

Non-ischemic, Control Group

Repetition is a useful way of increasing the percentage of success in scientific
processes. Although some factors were changed between runs, many factors
remained unchanged. Repeated processes became more robust because of the need
for the scientist to improve their technique. The repetition of the technique did
seem to yield better results; proportional to the number of times the process was
performed.

RESULTS
Some success was achieved from the modified alpha smooth muscle actin
IHC staining protocol. As listed in the table below, several staining outcomes were
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possible. Often, either the sectioning process or staining itself lead to too much
tissue loss to decipher the results of the stain. This issue was addressed in different
ways throughout the trials. For example, less time was spent in the dehydration
steps, and an air-dry step was added into the beginning of the stain. Also, sections
were more carefully chosen, so that the tissue started out with more integrity.
Additionally, extra care was taken when moving the slides vertically into or out of
reagents. The best procedure for maintaining tissue integrity has been included in
the optimized staining protocol (Appendix B).
Another common result of this study was “no distinction” between the
control and experimental groups. In other words, the tissues on the slides looked
about the same in shade and shade pattern, regardless of the presence or absence of
the primary antibody. These results are poor because, as described previously, the
chromagen should only have been developed where primary antibody had attached.
When the same brown coloring occurred in groups that were treated with primary
antibody and those that weren’t, the validity of the results in the experimental group
were questionable. That is, the brown shaded hypoxia maps obtained from tissues
treated with primary were probably not accurate, because the same hypoxia maps
were produced without the primary antibody. This suggested that non-specific
binding, or some factor other than hypoxia and the primary antibody, was playing a
role in staining the tissue, which lead to false positives and incorrect maps.
On the other hand, “no distinction” could also indicate false negative staining.
It was actually difficult to tell whether false positive or false negative staining had
occurred if ischemic control and ischemic primary tissues stained the same, because
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this study is based on relative shading (between primary and control groups).
Either way, if both the primary and control ischemic tissues came out the same, the
results were not accurate. In the results table, below, this outcome is simply named,
“no distinction”. Another form of “no distinction” was where, within primary
antibody treated groups, there was no difference in shading of tissue between
ischemic and non-ischemic tissues. This result probably did not reflect reality
because tissues that underwent induced ischemia should certainly have been more
hypoxic than tissues that did not. However, this distinction was absent in some
results. This disconnect indicated that either the ischemic tissues were not stained
in a way that properly represented their hypoxia, or that non-ischemic tissues were
stained such that more hypoxia was represented than actually existed. Either way,
the results were not reliable.
The more successful results are denoted in the results table as “distinction in
one slide”, “distinction in two slides”, or “distinction in some slides”. In these cases,
there were expected differences in shading between control groups and
experimental groups. Again, positive staining was only expected in one of four
scenarios: the tissue was ischemic and treated with primary antibody. When there
was clearly more shading (either in area or depth) in tissues that met this criteria
than tissues either without ischemia or without primary antibody, the stain was
successful. Never were the results clear across all slides in the run (usually about
eight slides total). As stated in the staining results table below, distinction either
occurred in one slide or some slides, but never in all slides. Modification of the
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injection and staining protocol and repetition of both techniques could increase the
percentage of success (from about 15% now).
Below is a summary of each stain and its results. The results for stain 2 that
read, “non-ischemic distinctions” refer to the specific issue of false positive staining
in tissue that should not have great amounts of hypoxia, because the vessel in the
hindlimb from which the tissue was not resected, and thus, ischemia was not
induced.
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Table 3. Staining Results
Results
No Distinction.
Distinction in some slides.
Non-ischemic distinctions.
Stain 3a 1
Calf
Appendix B 7
Distinction in one slide.
Stain 3b 2
Calf
Appendix B 7
No Distinction.
Stain 4a 2
Calf
Appendix B 7
Too much tissue loss.
Stain 4b 3
Calf
Appendix B 7
Too much tissue loss.
Stain 5a 2
Calf
Appendix B 7
Too much tissue loss.
Stain 5b 3
Calf
Appendix B 7
Too much tissue loss.
Stain 6
3
Calf
Appendix B 7
Distinction in two slides.
Stain 7a 2
Calf
Appendix B 7
Distinction in some slides.
Stain 7b 3
Gracilis Appendix B 7
No distinction.
Stain 7c 3
Calf
Appendix B 7
Distinction in some slides.
Stain 8a 2
Calf
Appendix B 3
Distinction in one slide.
Stain 8b 3
Calf
Appendix B 3
No distinction.
Note: Oven setting refers to the oven in Bonderson room 209. Setting 7 correlates
to over 100 °C, whereas setting usually results in 30-40 deg C.
Stain 1
Stain 2

Surgery
1
1

Tissue
Calf
Calf

Protocol
Appendix C
Appendix B

Oven setting
7
7

The results listed in the table above were observed visually using a whitelight microscope. The photomicrographs below show pairs of slides representing
various outcomes. Only the same tissue was compared between control and
experimental treatments, because the skeletal muscle architecture was so different
from tissue to tissue. No adjustments to the lighting, white balance, or zoom were
made on the microscope between the primary and control of each pair of photos.
Thus, if there was a difference in appearance between a pair of the same tissue, it
was due to the stain.
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Successful Stains

Figure 1a. Control

Figure 1b. Primary
non-ischemic
ischemic tissue. There is
Figure 1 shows successful results in non
no difference in shading between the control and primary groups
in the whole tissue. This was expected because the tissue was
non-ischemic,
ischemic, and should not have been hypoxic. Therefore, both
control and primary groups should be about equally unshaded.
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Figure 2a. Control

Figure 2b. Primary
Figure 2 also shows successful results in non
non-ischemic
ischemic tissue. As
seen in the zoomed image, there is very little difference in
contrast between the control and primary groups, as expected for
non-hypoxic
hypoxic tissue.

19

Figure 3a. Control

Figure 3b. Primary
Figure 3 shows successful results in ischemic tissue. There is an
obvious difference in overall shading between control and
primary groups, correctly representing hypoxia in the primary
group, as stained for using IHC. This shading seems not to be
regional, but rather, evenly spread through all tissue areas of the
experimental group. Although the tissue in figure 3a and 3b is the
same, and should have similar hypoxia levels in its sections,
hypoxia shouldn’t be depicted unless the tissue wass treated with
primary antibody.
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Figure 4a. Control

Figure 4b. Primary
Figure 4 features the same tissue sample as figure 3, however
figure 4’s image is magnified. Again, it is clear that the tissue
treated with primary antibody is generally darker than the
control. Additionally,
dditionally, the increased contrast seems to be located
evenly throughout the experimental tissue, not just in certain
areas.
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Figure 5a. Control

Figure 5b. Primary
Figure 5 shows a more localized form of success in an ischemic
tissue. Here, the ti
tissue
ssue treated with primary antibody shows dark
staining as compared to the control tissue in individual cells
rather than in overall shade. This localized response may be
closer to the expected hypoxic response of the tissue to ischemia.
It is possible that
at ischemia does cause a locally variable hypoxic
response.
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Unsuccessful Stains

Figure 6a. Control

Figure 6b. Primary
Figure 6 shows no distinction between control and primary
groups in an ischemic tissue. Becaus
Becausee the tissue is ischemic, dark
brown staining was expected for the primary group only, thereby
creating a difference in staining between control and primary
groups. The dark brown areas seen in the primary group are
simply the result of tissue folding, not successful staining.
Therefore,
ore, this stain was unsuccessful.
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Figure 7a. Control

Figure 7b. Primary
Figure 7 shows a magnified view of the tissue from figure 6.
Again, this slide was unsuccessful because, unexpectedly, there is
very little difference in shading between cont
control and primary
groups. Because there is no difference between groups, it cannot
be determined whether false positive or false negative staining
has occurred.
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Figure 8a. Control

Figure 8b. Primary
Figure 8 shows another unsuccessful stain in an ischemic tissue.
Again, as seen from the image of the whole calf cross
cross-section,
there is very little difference in contrast between the control and
primary treated tissue, even though the tissue is expected to be
hypoxic. In
n fact, there seems to be slightly more staining in the
control tissue than in the primary, which is opposite of the
expected hypoxic reaction in these two tissues. The stain was
unsuccessful because the primary treated tissue is not shaded
more than the control tissue.
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Figure 9a. Control

Figure 9b. Primary
Figure 9 shows a magnified view of the ischemic tissue from figure
8. Here, it is clear that the control group’s shading is slightly more
defined than is the experimental group’s. In this case, the control
group may be falsely positive and the primary group may be
falsely negative.
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Figure 10a. Control

Figure 10b. Primary
Figure 10 shows more contrast in the primary tissue than in the
control tissue. This result would be expect
expected
ed had the tissue been
ischemic, but the tissue is non
non-ischemic. Because of this, little
hypoxia is expected, and therefore there would be little staining,
regardless of whether the sample was treated with primary
antibody or not. This result is unsucces
unsuccessful at accurately
displaying the location of hypoxia.
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Figure 11a. Control

Figure 11b. Primary
Figure 11 displays a magnified view of the tissue in figure 10.
Although it is slight, the shading in the experimental group may
be more defined than the shading in the control group. Again, this
stain is unsuccessful. Both groups are expected to have little to no
shading due to the lack of ischemia in the tissue.
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Figure 12.
Figure 12 shows a sample that has had too much tissue loss for
staining analysis.
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DISCUSSION
There were some successful results of this study, supporting the proof-ofconcept for mapping hypoxia in mouse hindlimb skeletal muscle. Although there
were some false positives in every batch, the validity of the successful slides is not
undermined. However, instead of using successful slides as definitive victories, they
must be looked at as possibilities of future success. Although it can’t be told if the
successful-looking slides represent accurate maps of hypoxia in the tissue used, the
more frequently these successful results occur, the more likely this is the case.
There were also unsuccessful slides. In general, “no distinction where there
should have been”, and “distinction where there should not have been” were the two
incorrect outcomes that occurred. These false positives or false negatives indicate
either over-staining of non-hypoxic cells or under-staining of hypoxic cells. The
incorrect stains could be the result of mistakes in technique or logic in injection,
surgery, processing and embedding, sectioning, or staining.
The lack of staining where there should be (false negative) or the presence of
staining where there should not have been (false positive) are both logical
possibilities for results that have no distinction in tissue shading between control
and experimental groups. However, it is difficult to distinguish which scenario has
played out, because success was measured in this study by comparison between
samples. Therefore, if there was no distinction between an ischemic control tissue
and an ischemic experimental tissue, it was deducible that the run was unsuccessful,
but it was hard to discern more than that. Postulations have been made, however,
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as to what has caused some of the poor results. No distinction would be apparent
where expected if the surgery did not cause significant hypoxia. Many things could
go wrong with the injection, resection, and dissection technique and timeline,
resulting in an unnoticeable change in hypoxia levels. In this case, the negative
would not be false, but unexpected. Moreover, because the blocking serum bound to
and blocked open binding sites, if the tissue was treated with blocking serum out of
sequence, false positive staining would have occurred. Finally, underexposure to
DAB is a condition that could possibly lead to false negatives. DAB needed time to
develop into a brown hue, and if this time was not allowed, little or no staining may
have been seen. On the other hand, false positive results may have been caused by
non-specific binding of antibodies. The technique of immunohistochemistry
depends on specificity between antigens and antibodies. For example, if the binding
of primary antibody was not specific to pimonidazole, not only hypoxic cells would
be stained. Additionally, false positive staining could be caused by over-exposure to
DAB. Because both false positive and false negative staining occurred in most trials,
a combination of the issues mentioned probably occurred.
More successful slides per run and the limitation of false positive and false
negative slides are desirable goals. To do this, there are many avenues for protocol
modifications. It is the hope that one or a combination of some of the following
suggestions may help to increase the ratio of good slides to bad slides. The
suggestions for the future are as follows:
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Table 4. Future Suggestions
Alter the surgery timing to allow for better circulation of pimonidazole, more
hypoxia, or better binding of pimonidazole to hypoxic cells
Alter the exposure time of the samples to the DAB chromagen
Use the staining protocol provided by Hypoxyprobe (Appendix C)
Keep the oven setting as low as 3 or 4 (so as not to damage the tissue)
Use other hindlimb tissues
Use more repetition and larger sample sizes to override technique problems

The successes achieved in this study have validated, in part, the developed
protocol for hypoxia mapping in ischemic mouse hindlimb skeletal muscle. It is true
that the protocol, which produces consistent true positive results, needs to be
further developed, but that protocol could be largely based on the one used in this
study. Much has been discovered about the nature of immunohistochemical
staining in hypoxic mouse tissue, and these discoveries can be used to further
perfect the hypoxia mapping technique.
The developed injection and staining technique can be used by the
microcirculation lab to asses the presence of hypoxia near the muscular branch
artery. Vascular reactivity measurements have already been, and continue to be,
collected from this area, so adding the developed procedure for hypoxia mapping
may help draw connections between regional oxygen levels and vascular function.
Hypoxia's role in vasuclar reactivity, whether it be in vessel growth, or in vessel wall
functionality, may be established with this or subsequent modifications of this
protocol.
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APPENDIX
Appendix A: Injection Protocol

Injection Protocol
Interpreted by Emily Deckert, August, 2010
This protocol can be altered to achieve better results. What is written has not yet
been verified to be the best injection method. Things to alter include timing,
fixatives, and temperatures. Additionally, after the injection and staining protocol
have been optimized for use in the lab as a method to map hypoxia, this injection
protocol can be altered to work in conjunction with other studies involving the
animal.
•

•

•

•

•

•
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Timing:
o Injection
o Resection
o Stimulation
o Dissection
o Fixation
Injection:
o Intraperitoneal
o Solution: 250 µL PBS, 1.8 mg pimonidazole per mouse
o Hypoxyprobe injection at room temp, store in fridge, but do not
freeze.
Resection:
o Following current lab protocol
o Only resect one limb. The other will serve as a control.
Stimulation:
o Optional
o Using the lab’s electrodes, stimulate the calf for 90 seconds: 8 Hz, 0.5
ms, 2 mA
Dissection:
o 15 to 90 minutes (or 1-2 hours) after injection (Hypoxyprobe will be
“frozen” in place at the time of harvest).
o Actual harvest time as quick as possible.
Fixation:
o Immersion fixation in formalin
o Let sit in fixative over night at room temp

Appendix B: Staining Protocol

Immunohistochemcial Hypoxia Staining Protocol
Emily Deckert, August 2010
Adapted from protocols from Chris Miracle and Santa Cruz Biotechnology
1. Incubate slides for 5 – 10 minutes in oven after sectioning
a. Prepare blocking serum. Mix in blue bottle.
i. 75 µL normal goat blocking serum stock
ii. 5 mL PBS
2. Dip with Xylene – 10 min
3. Air dry – 30 sec
4. Dip with 100% ethanol – 2 min
5. Air dry – 30 sec
6. Dip with 95% ethanol – 1 min
7. Incubate slides (room temperature) with blocking serum – 1 hour*
a. Prepare primary antibody 30 – 45 minutes into step 7. Mix in
disposable centrifuge tube.
i. Pipette 30 µL Hypoxyprobe İgG mouse monoclonal antibody
(with an antibody solution concentration of 70 µg/mL)
ii. Pipette 970 µL blocking serum
(The resulting antibody solution concentration is 2 µg/mL)
b. Suction reagent (blocking serum) after 1 hour**
i. Suction 1 slide at a time, proceed to step 8 and repeat for each
slide
8. Incubate slides (room temperature) with primary antibody – 30 min
9. Wash with 3 changes of PBS – 5 min each
a. During these washes, prepare secondary antibody. Mix in green
bottle.
i. 75 µL normal blocking serum stock
ii. 5 mL PBS
35

iii. 25 µL secondary antibody stock
10. Incubate slides (room temperature) with secondary antibody solution –
30 min
a. During this step, prepare AB enzyme reagent. Mix in purple bottle.
i. 50 µL avidin
ii. 50 µL biotinylated horse radish peroxidase (HRP)
iii. 2.5 mL PBS
11. Wash with 3 changes of PBS – 5 min each
12. Incubate slides (room temperature) with AB enzyme (having allowed
the AB enzyme to sit for 30 minutes)– 30 min
13. Wash with 3 changes of PBS – 5 min each
a. During these washes, prepare peroxidase substrate. Mix in yellow
bottle.
i. 1.6 mL distilled water
ii. 5 drops 10X substrate buffer
iii. 1 drop 50X DAB chromogen
iv. 1 drop 50X peroxidase substrate
14. Incubate with peroxidase substrate – 5 min
15. Wash in distilled water – 4 min
16. 95% ethanol – 10 sec
17. 100% ethanol – 10 sec
18. Xylene - 25 sec
19. Coverslip each slide individually and prior directly from xylene
*Note: Use a food container dish with a moist paper towel on the bottom to
create a moist chamber environment for incubating both inside and outside
of the hood for all incubation steps.
**Note: Use suction pump/vacuum to remove reagents one at a time between
all incubation steps
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Appendix C: Alternate Staining Protocol

Immunohistochemical Hypoxia Staining Protocol (Alternate)
Interpreted by Emily Deckert, August, 2010
Provided by Hypoxyprobe İnc.
1.
2.
3.
4.
5.
6.
7.
8.
9.
1)

2)

3)

Warm paraffinized tissue section. 40°C, 20 min.
Dip and blot 10 times (slides held vertically): xylene, 2 min.
Dip and blot 10 times (slides held vertically): 100% ethanol, 2 min.
Dip and blot 10 times (slides held vertically): 95% aqueous ethanol, 2 min.
Dip and blot 10 times (slides held vertically): 80% aqueous ethanol, 2 min.
Dip and blot 10 times (slides held vertically): D.İ. H20 + 0.2% Brij 35, 2 min.
Dip and blot 10 times (slides held vertically): PBS + 0.2% Brij 35, 2 min.
Incubate (slides held vertically): 3% H2O2 in distilled water, 5 min.
Choose 1, 2, or 3:
“Heat treatment (recommended method): Place slides in a container and cover with 10
mM sodium citrate buffer, pH 6.0; or with 50 mMglycine-HCl buffer (glycine: sc29096), pH 3.5, with 0.01% (w/v) EDTA (EDTA: sc-29092). Heat at 95º C for 5
minutes. Top off with fresh buffer and heat at 95º C for 5 minutes (optimal incubation
time may vary for each tissue type). Allow slides to cool in the buffer for
approximately 20 minutes. Wash in deionized H2O three times for 2 minutes each.
Aspirate excess liquid from slides.”
“Pepsin: Incubate sections for 10–20 minutes in 0.1% pepsin in 0.01 N HCl at room
temperature. Wash slides several times in deionized H2O. Aspirate excess liquid from
slides.”
“Saponin: Incubate sections for 30 minutes in 0.05% saponin in deionized H2O at room
temperature. Wash at least three times in PBS. Aspirate excess liquid from slides.”

(Santa Cruz Biotechnology, 2010)
10. Wash: PBS + 0.2% Brij 35, 0°C, 2 min. Reagent magnetically stirred in a
Coplin jar held on ice.
11. İncubate (slides held horizontally): Blocking solution, 5 min. (ABC Kit)
12. İncubate (slides held horizontally): 1/50 Primary Antibody (for
Hypoxyprobe, see reagent directions), 40 min.
13. Wash (slides held horizontally): PBS + 0.2% Brij 35, 0°C, 2 min. Reagent
magnetically stirred in a Coplin jar held on ice.
14. Incubate(slides held horizontally): 1/500 secondary antibody in 10 mM PBS,
with 0.2% Brij 35 and 1 drop protein blocker /mL, 10 min. (ABC Kit)
15. Wash (slides held horizontally): PBS + 0.2% Brij 35, 0°C, 2 min. Reagent
magnetically stirred in a Coplin jar held on ice.
16. Incubate (slides held horizontally): Peroxidase substrate, 10 min. (ABC Kit)
17. Wash (slides held horizontally): PBS + 0.2% Brij 35, 0°C, 2 min. Reagent
magnetically stirred in a Coplin jar held on ice.
18. Incubate (slides held horizontally): Peroxidase chromagen (DAB), 10 min.
(ABC Kit)
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19. Wash (slides held horizontally): distilled H20, 2 min. Reagent magnetically
stirred in a Coplin jar.
20. Incubate: Hematoxylin, 30 seconds.
21. Wash (slides held horizontally): distilled H20, 2 min. Reagent magnetically
stirred in a Coplin jar.
22. Crystal/Mount, 20 min.
(Hypoxyprobe, 2010)
Purposes:
• 2-7: depariffinization, hydration
• 8: quench tissue peroxidase
• 9: antigen retrieval
• 11: Block non-specific binding
• 16, 18: color
• 20: counterstain
• 22: mount and dry slides
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Appendix D: Staining Log

Stain 1

Date
7-13-10

Stain 2

7-16-10

Stain 3a

7-17-10

Stain 3b

7-17-10

Stain 4a
Stain 4b
Stain 5a
Stain 5b
Stain 6
Stain 7a
Stain 7b
Stain 7c
Stain 8a
Stain 8b
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Blocks
10-210
10-211 (i)
10-210
10-211 (i)

Surgery
1

Tissue
Calf

Photo
none

1

Calf

10-210
10-211 (i)

1

Calf

Figure 1 (210 A)
Figure 5 (211 A)
Figure 10 (210 C)
Figure 11 (210 C)
Figure 2 (210 B)
Figure 3 (211 C)
Figure 4 (211 C)
none

10-222
2
Calf
10-223 (i)
7-24-10
10-222
2
Calf
Figure 12 (223 D)
10-223 (i)
7-24-10
10-235
3
Calf
none
10-236 (i)
7-25-10
10-222
2
Calf
none
10-223 (i)
7-25-10
10-235
3
Calf
none
10-236 (i)
7-26-10
10-235
3
Calf
none
10-236 (i)
7-30-10
10-222
2
Calf
Figure 8 (223 D)
10-223 (i)
Figure 9 (223 D)
7-30-10
10-233
3
Gracilis none
10-234 (i)
7-30-10
10-235
3
Calf
none
10-236 (i)
7-31-10
10-222
2
Calf
Figure 6 (223 E)
10-223 (i)
Figure 7 (223 E)
7-31-10
10-235
3
Calf
none
10-236 (i)
Blocks denoted by an “(i)” contain ischemic tissues.

Appendix E: Hypoxyprobe TM -1 Kit İnformation
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